What Biofibrat Treats: Main Uses and Benefits

Biofibrat is applied across domains where additional symptomatic support is needed, used in situations involving certain distressing symptoms. The medication is especially relevant in contexts marked by increased discomfort or tension. It helps address symptom clusters that may become intense or disruptive, such as those associated with conditions presenting with acute episodes and recurrent or episodic manifestations.

---

Key Therapeutic Focus

This medicine is commonly used across conditions where symptoms escalate temporarily, providing support that helps ease the overall symptom load. It provides supportive relief when symptoms interfere with routine activities. It is often used when symptoms intensify and supportive relief is needed. It helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Supports Management of Symptom Clusters

---

Easing Symptom Clusters Causing Daily Strain

Applied in clinical settings that involve acute or disruptive symptom patterns, Biofibrat is relevant for managing symptoms that interfere with daily comfort and create noticeable physiological strain. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations during difficult episodes. It is relevant for easing distress and contributing to improved day-to-day comfort.

Biofibrat (Fenofibrate) is approved for use in adult patients (18 years and older) who do not present with specific contraindications. Eligibility is strictly determined by a patient’s age, reproductive status, and the presence of critical comorbidities affecting major organs.

Populations for Whom Use is Contraindicated

Official regulatory labeling dictates that Biofibrat is contraindicated and must not be used in the following populations:

• Patients with Severe Renal Impairment, including those on dialysis.
• Patients with Active Liver Disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities.
• Patients with Pre-existing Gallbladder Disease.
• Nursing Mothers (Breastfeeding).
• Patients with known Hypersensitivity (allergy) to fenofibrate or fenofibric acid.

Age and Condition-Based Restrictions

Classification	Population Group	Regulatory Status
Pediatric	Children and Adolescents (under 18)	Use Not Established; not recommended.
Renal Function	Mild to Moderate Impairment	Use is permitted, but requires a dose reduction.
Pregnancy	Pregnant Women	Restricted Use; only if the potential benefit justifies the potential risk to the fetus.
Comorbidity	Chronic or Acute Pancreatitis	Contraindicated (except for acute pancreatitis due to very high triglycerides).

Use in the older adult population is generally permitted, but eligibility must be assessed primarily based on their renal function status.

Interactions with other medicines and products

Biofibrat, which contains Fenofibrate, has officially documented interaction patterns primarily concerning pharmacodynamic risk reinforcement and alterations in the exposure of co-administered substances. Regulatory documents define restrictions and monitoring requirements for several drug classes.

---

Documented Interaction Constraints

• Other Fibrates (e.g., Gemfibrozil): Co-administration is generally avoided or contraindicated due to an officially documented, significantly increased risk of muscle toxicity (myopathy and rhabdomyolysis).
• Statins and Colchicine: Concomitant use increases the officially documented additive risk of myopathy and rhabdomyolysis.
• Coumarin Anticoagulants (e.g., Warfarin): Fenofibrate officially potentiates the anticoagulant effect, requiring frequent monitoring of Prothrombin Time (PT) and International Normalized Ratio (INR).
• Immunosuppressants (e.g., Cyclosporine): Concomitant use increases the potential for nephrotoxicity (kidney damage), which necessitates monitoring of renal function.

---

Administration Timing and Population Notes

Bile Acid Resins (e.g., Cholestyramine) significantly impede Fenofibrate's absorption. Administration must be separated, with Fenofibrate taken at least one hour before or four to six hours after the resin. Furthermore, the risk of myopathy with statins is officially heightened in specific populations, including the elderly and patients with renal failure or uncontrolled hypothyroidism.

How Biofibrat Works: Mechanism of Action

Biofibrat's action is executed by its active metabolite, fenofibric acid, which functions as a molecular regulator of lipid processing by influencing gene expression. The core mechanism involves binding to and activating the Peroxisome Proliferator-Activated Receptor alpha (PPARα), a nuclear receptor that controls the transcription of key metabolic genes.

This specific agonism initiates a sequence that leads to the upregulation of Lipoprotein Lipase (LPL) activity, an enzyme that hydrolyzes circulating triglycerides, while simultaneously suppressing Apolipoprotein C-III (ApoC-III), a negative regulator of LPL. This dual action enhances the systemic catabolism and clearance rate of triglyceride-rich VLDL and chylomicron particles, resulting in a net decrease in their circulating concentrations.

Furthermore, the drug's action modulates the components of High-Density Lipoprotein (HDL) by boosting the synthesis of its structural proteins, Apolipoprotein A-I (ApoA-I) and ApoA-II. This modulation of apolipoprotein production facilitates the formation of HDL particles, which are involved in reverse cholesterol transport.

Administration and Dosing Instructions

Biofibrat (fenofibrate) is administered orally as a capsule or tablet and is typically taken once daily. The instructions for use detail the required administration method, schedule, and dosage adjustments based on specific patient factors.

Official Administration Guidelines

Administration Scope	Instruction
Route of Administration	Oral
Frequency and Timing	Once daily, at any time of day, and may be taken with or without food.
Preparation Requirements	Capsules or tablets must be swallowed whole. Do not crush, break, dissolve, or chew the medication.
Special Co-administration	If you are also taking a bile acid binding resin (such as cholestyramine), Biofibrat must be taken at least 1 hour before or 4 to 6 hours after the resin to prevent interference with drug absorption.

Dosage Adjustment and Monitoring

• Dosage Individualization: The correct dosage is individualized based on patient response, which is assessed by a healthcare provider using lipid determinations (blood tests) at 4 to 8 week intervals.
• Renal Impairment: For patients with mild to moderate kidney function impairment (eGFR 30 to <60 mL/min/1.73m^2), treatment must be initiated at a lower starting dose (e.g., 43 mg or 48 mg once daily) and increased only after careful evaluation of effects on kidney function and lipid levels.
• Missed Dose: If a dose is missed, patients are advised to skip the missed dose and resume treatment with the next dose at the regular scheduled time. Do not take an extra or double dose to make up for the one missed.
• Discontinuation: If an adequate response is not achieved after two months of treatment with the maximum recommended dose, the medication should be discontinued.

Research Evidence / Overview of Studies for Biofibrat

Evidence for Use in Myelofibrosis

Research exploring Biofibrat's role for patients with myelofibrosis has been based largely on Phase 3 randomized controlled trials (RCTs). These studies served as the basis for research exploring how symptoms change over time and in trials assessing short-term symptom patterns. Study populations included adult patients with primary myelofibrosis, or myelofibrosis that developed following polycythemia vera (PV) or essential thrombocythemia (ET).

The research focused on tracking changes in the size of the spleen and monitoring patient-reported outcomes, specifically looking at total symptom score, which includes symptoms like fatigue. Some trials described patterns such as a measured reduction in spleen volume and changes in symptom scores in a defined percentage of the studied population. Research highlights changes measured during the study period, but research does not determine whether an individual will respond similarly.

Evidence for Hyperlipidemia and Cardiovascular Research

Biofibrat was also evaluated in large-scale, long-term clinical trials relevant for its use in hyperlipidemia (high blood fats). These studies explored outcomes by monitoring changes in certain types of blood fat levels, such as triglycerides and HDL cholesterol. The research also examined long-term outcomes, such as the patterns in the occurrence of cardiovascular events, over multi-year follow-up periods.

Understanding Long-Term Studies and Durability of Response

A key area of research is the long-term impact of Biofibrat. While research explored short-term symptom changes, long-term effects are not fully established. Studies monitored patients to assess the duration of observed outcomes. However, there is limited information for long-term outcomes, especially regarding overall survival patterns over many years, as follow-up durations were limited in the initial studies.

What Remains Uncertain About Biofibrat Research

The existing evidence base contributes to the broader evidence landscape but has several limitations. Long-term effects are not fully established, and research may lack data from studies directly comparing Biofibrat to all alternative therapeutic approaches. Subgroup findings are uncertain, as results apply only to the populations studied, and sample sizes were modest for specific groups, providing limited insight. Research is ongoing to address these gaps.

Key Studies & References

1. COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial - ClinicalTrials.gov (NCT00952289)

Common questions about Biofibrat (FAQ)

Q: What is the main difference between Biofibrat and other cholesterol-lowering drugs?

A: Biofibrat belongs to the fibrate class of medicines and is approved to address dyslipidemia, which involves reducing elevated triglycerides and certain types of cholesterol, and increasing HDL (the 'good' cholesterol). Its core mechanism is to activate a specific cellular receptor, PPARalpha, which enhances the body's natural breakdown and clearance of fat molecules, particularly those rich in triglycerides.

Q: Why is Biofibrat sometimes prescribed when a statin drug is not tolerated?

A: Biofibrat is from a different pharmacological class than statins. Official regulatory indications state that Biofibrat is used for conditions such as primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. A healthcare provider uses this information to determine which treatment is appropriate based on a patient's specific lipid profile and medical needs.

Q: Is Biofibrat known to cause any long-term damage to the liver or kidneys?

A: Official information indicates that the medication can cause elevated liver enzymes (hepatotoxicity) and increases in serum creatinine, which is a kidney marker. Regulatory labeling mandates routine monitoring of these levels. Furthermore, the risk of serious muscle problems (rhabdomyolysis) is officially noted to be higher in people with impaired kidney function.

Q: Are headache or dizziness considered normal side effects of Biofibrat?

A: Regulatory documents report headache as an adverse reaction. Some official patient information also includes dizziness as a possible side effect of the medication. The frequency of these effects varies among individuals.

Q: Does Biofibrat cause digestive issues like diarrhea, stomach cramps, or gas?

A: Reported common side effects include general gastrointestinal signs and symptoms, such as abdominal pain and constipation. Other digestive issues reported in official sources include diarrhea and general stomach discomfort.

Q: What are the signs of a serious muscle problem related to Biofibrat?

A: Serious muscle problems, such as rhabdomyolysis, are rare but possible. Official safety documentation indicates that unexplained muscle pain, tenderness, or weakness, particularly if accompanied by general malaise or a fever, are signs that must be brought to the attention of a healthcare provider.

Q: What happens if I stop taking Biofibrat, and will my lipid levels go back up?

A: Regulatory documents address discontinuing treatment if an adequate response is not achieved after two months. When any lipid-regulating medication is stopped, the effects of the drug cease. This means that if the underlying condition is still present, lipid levels may trend toward the levels measured before treatment was initiated.

Q: Is it true that Biofibrat helps lower very high triglycerides, preventing pancreatitis?

A: The medication is used for the treatment of severe hypertriglyceridemia (very high blood fat levels). While markedly elevated triglycerides can increase the risk of pancreatitis, official labeling states that the effect of Biofibrat therapy on specifically reducing this risk has not been adequately established in research studies.

Q: What should I do if I notice yellowing of the skin or eyes while taking Biofibrat?

A: Yellowing of the skin or the whites of the eyes (jaundice) can be a sign of potential liver problems. Regulatory safety documents indicate that any such sign of potential hepatotoxicity must be brought to the attention of a healthcare provider.

Q: Is there any research comparing Biofibrat's effect on heart disease risk to statins?

A: Official labeling references clinical trials which examined the effects of Biofibrat on cardiovascular events. One major study found that fenofibrate was not shown to reduce coronary heart disease morbidity or mortality in patients with type 2 diabetes mellitus. The label does not contain a definitive comparative statement regarding heart outcomes versus statins.

Q: Does Biofibrat lower all types of cholesterol, like LDL and total cholesterol?

A: Official product information states that Biofibrat is indicated to reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) and Total Cholesterol, in addition to its primary action of lowering triglycerides.

Q: Do side effects from Biofibrat usually become less noticeable over time?

A: Regulatory sources generally indicate that mild side effects associated with many medications may subside within a few days or weeks after starting treatment. If side effects persist or are bothersome, a healthcare professional should be contacted.

Q: Is it possible for Biofibrat to affect my sleep (e.g., cause insomnia or tiredness)?

A: Official safety data indicates that effects such as unusual tiredness or weakness and fatigue are reported as part of potential muscle-related symptoms. Insomnia is not typically listed as an effect in the primary regulatory documentation.

Q: How does Biofibrat affect blood sugar or glucose levels, especially for people with diabetes?

A: Official information on drug interactions notes that taking Biofibrat at the same time as certain diabetes medications, such as sulfonylureas, may increase the risk of low blood sugar (hypoglycemia). This interaction necessitates regular monitoring of blood sugar levels by a healthcare provider.

Q: Does Biofibrat interact with common pain relievers like Tylenol or ibuprofen?

A: Regulatory information indicates that fenofibrate may increase the concentration and effects of certain pain relievers, including acetaminophen (Tylenol) and ibuprofen (a nonsteroidal anti-inflammatory drug or NSAID). Co-administration of these medications may necessitate medical monitoring.

Q: Can I drink alcohol while I am taking Biofibrat?

A: Official patient information indicates that consuming large quantities of alcohol may increase the potential risk of liver problems associated with the medication. It is generally noted that patients should inform their healthcare provider about their alcohol consumption.

Q: Are there any specific dietary restrictions or foods to avoid while taking Biofibrat?

A: While the US label states the medication may be taken with or without food, some regulatory labeling specifically notes that grapefruit juice should be avoided when taking certain fenofibrate-containing products.

Q: Is it safe to drive or operate machinery while taking Biofibrat?

A: Official patient information indicates that fenofibrate may cause dizziness in some people. Patients should use caution regarding driving or operating machinery until they are aware of how the medication affects their physical state.

Q: Does Biofibrat have a generic version available and is it the same as the brand name?

A: Regulatory sources confirm that fenofibrate is the active ingredient and is available in multiple generic formulations. Generic versions of a medication contain the same active ingredient as the brand name product.

Q: Can Biofibrat cause a skin rash or increased sensitivity to the sun?

A: Official labeling notes that the medication can cause severe skin reactions, including rash, and can make individuals more sensitive to sun exposure. Official recommendations generally advise avoiding excessive sunlight.

Q: Do other medicines I take need to be adjusted when starting Biofibrat?

A: Yes, regulatory documents indicate that the dosage of some other medicines, specifically Coumarin anticoagulants (such as Warfarin), may need to be adjusted. Biofibrat can potentiate the anticoagulant effect, which requires frequent monitoring of blood parameters to ensure appropriate dosing.

Q: Is a runny nose or sneezing a reported side effect of Biofibrat?

A: Official safety data confirms that runny or stuffy nose (rhinitis) and sneezing are among the reported adverse reactions that may be experienced while taking Biofibrat.

Q: Will I need to take Biofibrat for the rest of my life?

A: The duration of therapy for dyslipidemia is generally expected to be long-term, but official regulatory instructions state that therapy should be withdrawn if an adequate lipid-lowering response is not achieved after two months. The decision on the total duration of treatment is made by a healthcare provider based on the patient's condition.

Q: How does Biofibrat affect the body's absorption of other nutrients or vitamins?

A: Some regulatory patient information notes that taking the medication may cause a decrease in Vitamin B12 levels. Regulatory guidance notes the importance of ensuring sufficient Vitamin B12 intake when taking the medication.

Q: Can Biofibrat cause changes in appetite or weight?

A: Official sources list decreased appetite and weight loss as potential symptoms that may accompany liver problems associated with the medication.

Q: Does Biofibrat interfere with fertility in men or women?

A: Nonclinical toxicology studies performed in male rats, as documented in regulatory files, indicated that the medication caused an impairment of fertility at high doses.

Q: Can Biofibrat cause any issues with my blood clotting?

A: Official safety information notes an association with a risk of venothromboembolic disease, which involves blood clots. Furthermore, the drug can potentiate the effects of blood thinners like Coumarin anticoagulants, increasing the risk of bleeding.

Q: What are the most serious warnings associated with taking Biofibrat?

A: Official warnings and precautions sections outline several serious potential risks. These include liver toxicity (Hepatotoxicity), severe muscle breakdown (Myopathy and Rhabdomyolysis), gallstones (Cholelithiasis), pancreatitis, and severe allergic or hypersensitivity reactions.

Official Storage Requirements

Biofibrat (Fenofibrate) must be stored at Controlled Room Temperature (CRT), maintained between 20 C and 25 C (68 F and 77 F). To protect the medicine, it must be kept in its original, tightly closed container and protected from excessive moisture and light. It is a mandatory requirement to avoid freezing and to ensure the product is not subjected to temperatures above 30 C (86 F).

Handling and Child Safety

To preserve the product’s stability until the expiration date, ensure the container remains tightly sealed. As a safety measure, Biofibrat must always be kept out of the reach of children.

Disposal Instructions

Regulatory guidelines require that unused or expired Biofibrat must not be disposed of in household trash or poured down a drain. To comply with environmental and public health standards, the medicine should be disposed of by taking it to a local pharmaceutical drug take-back program or a pharmacy collection point.